CKAP2 Regulated by TFDP1 Promotes Metastasis and Proliferation of Colorectal Cancer through Affecting the Tumor Microenvironment

Zhiqiang Zhong, Shi Cheng, Yang LiuJournal of Microbiology and Biotechnology 2024 · DOI

TL;DR

This study identifies Cytoskeleton Associated Protein 2 (CKAP2) as a key driver of colorectal cancer (CRC) progression, promoting metastasis and proliferation by influencing the tumor microenvironment. The research demonstrates that CKAP2's activity is regulated by the transcription factor TFDP1, offering potential new therapeutic targets for CRC.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a significant global health challenge, and current diagnostic and prognostic tools have limitations. The need for effective biological targets to better understand and treat CRC is critical. While some proteins are known to be involved in cancer, the specific roles of many, including CKAP2, in CRC progression and metastasis are not fully elucidated. This paper aims to fill this knowledge gap by investigating the function of CKAP2 in CRC, its regulatory mechanisms, and its impact on the tumor microenvironment.

Methods

The researchers employed a multi-faceted approach to investigate CKAP2's role in CRC:

  • Gene Expression Analysis: qRT-PCR was used to quantify CKAP2 mRNA levels in CRC cell lines and normal cells.
  • Protein Expression Analysis: Western blotting, immunohistochemistry (IHC), and immunofluorescence assays were used to detect CKAP2 protein levels in cells and tissues, as well as other key proteins like E-cadherin, N-cadherin, TFDP1, CD86, CD206, and CD31.
  • Functional Assays:
    • Cell Proliferation: CCK-8 and EdU assays were used to assess the impact of CKAP2 manipulation on cell viability and proliferation.
  • Cell Migration and Invasion: Transwell assays were employed to evaluate the effects of CKAP2 on cell movement and invasion capabilities.
  • Epithelial-Mesenchymal Transition (EMT): Western blotting was used to examine the expression of EMT markers (E-cadherin and N-cadherin).
  • Tumor Microenvironment (TME) Modulation: * Macrophage Differentiation: Immunofluorescence and ELISA were used to assess the influence of CKAP2 on the polarization of tumor-associated macrophages (TAMs) towards an M2 phenotype, and the secretion of related cytokines (IL-1β and CCL17).
  • Angiogenesis: Tube formation assays and immunofluorescence for CD31 were used to evaluate CKAP2's effect on the proliferation and tube-forming ability of human umbilical vein endothelial cells (HUVECs).
  • Molecular Interaction Studies:
    • Bioinformatics Prediction: The JASPAR database was used to predict potential binding sites of TFDP1 on the CKAP2 promoter.
  • Dual-Luciferase Reporter (DLR) Assay: This assay confirmed the interaction between TFDP1 and the CKAP2 promoter.
  • Co-Immunoprecipitation (Co-IP) Assay: This technique was used to experimentally confirm the physical interaction between CKAP2 and TFDP1 proteins.
  • In Vivo Studies:
    • Tumorigenesis Assay: Subcutaneous injection of CRC cells into nude mice was used to assess the effect of CKAP2 silencing on tumor growth.
  • Metastasis Assay: Luciferase-labeled CRC cells were injected intravenously into mice to monitor lung metastasis using IVIS imaging. Hematoxylin and Eosin (HE) staining was used for histological confirmation of lung metastasis.

Datasets

  • Public Databases: The Cancer Genome Atlas (TCGA) colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ) datasets were analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) database. The GEO database (GSE143939) was also utilized for gene expression analysis.
  • Cell Lines: Human CRC cell lines (HT29, HCT116, SW480, LOVO, SW620) and normal human colon epithelial cells (FHC) were used. THP-1 cells were used to generate macrophages. HUVECs were used to study angiogenesis.
  • Animal Models: Male nude mice (BALB/c) were used for in vivo experiments.

Key Insights and Ideas

  • CKAP2 as an Oncogene in CRC: The study strongly implicates CKAP2 as a driver of CRC, showing that its high expression correlates with increased proliferation, migration, invasion, and EMT. This suggests CKAP2 is not just a marker but an active participant in cancer progression.
  • CKAP2's Influence on the Tumor Microenvironment: A critical finding is CKAP2's ability to modulate the TME. It promotes the differentiation of macrophages towards an M2 phenotype, which is generally associated with immune suppression and tumor promotion. Furthermore, CKAP2 enhances angiogenesis by promoting HUVEC proliferation and tube formation, providing essential support for tumor growth and metastasis.
  • TFDP1 as a Regulator of CKAP2: The research uncovers a direct regulatory relationship between the transcription factor TFDP1 and CKAP2. TFDP1 appears to bind to the CKAP2 promoter, influencing its expression. This provides a molecular link between a known transcription factor and the newly identified oncogene.
  • Reversal of TFDP1 Knockdown Effects by CKAP2 Overexpression: The study demonstrates that when TFDP1 is downregulated (which is expected to inhibit CRC progression), overexpressing CKAP2 can partially reverse these inhibitory effects. This highlights the critical role of CKAP2 in mediating TFDP1's impact on CRC.
  • In Vivo Efficacy of CKAP2 Silencing: The in vivo experiments provide compelling evidence that reducing CKAP2 levels significantly inhibits tumor growth and metastasis in mice, validating CKAP2 as a promising therapeutic target.

Key Results

  • CKAP2 expression was significantly upregulated in CRC cells and tissues compared to normal counterparts.
  • Silencing CKAP2 in CRC cells led to a marked reduction in proliferation, migration, invasion, and EMT.
  • CKAP2 overexpression in CRC cells promoted M2 macrophage polarization and increased the secretion of IL-1β and CCL17.
  • CKAP2 promoted HUVEC proliferation and angiogenesis.
  • TFDP1 was identified as a direct regulator of CKAP2 expression, with TFDP1 overexpression increasing CKAP2 levels and TFDP1 downregulation decreasing them.
  • Overexpression of CKAP2 could partially rescue the inhibitory effects of TFDP1 downregulation on CRC cell proliferation, migration, and invasion.
  • In vivo, CKAP2 silencing significantly suppressed tumor growth and lung metastasis in nude mice.

Limitations and Future Work

  • Complexity of TME: While the study highlights CKAP2's impact on macrophages and angiogenesis, the tumor microenvironment is highly complex. Further research could explore CKAP2's interactions with other TME components, such as fibroblasts and other immune cells.
  • Therapeutic Translation: The findings suggest CKAP2 as a therapeutic target, but further preclinical and clinical studies are needed to develop and validate CKAP2-targeting therapies.
  • Mechanism of TFDP1-CKAP2 Interaction: While the interaction is confirmed, the precise molecular mechanisms by which TFDP1 regulates CKAP2 expression (e.g., specific binding sites, co-factors) could be further elucidated.
  • Broader Cancer Types: The study focuses on CRC. Investigating CKAP2's role in other cancer types could reveal broader therapeutic potential.

Summary updated

Abstract

The current pathological and physiological evaluation system for colorectal cancer (CRC) is limited; thus, effective biological targets to diagnose and treat this disease are urgently needed. In this study, we used qRT-PCR for detecting mRNA levels of genes. The levels of protein were identified by western blot, immunohistochemistry, and immunofluorescence assays. In addition, functional experiments were used to evaluate the role of cytoskeleton associated protein (CKAP) 2 in CRC cells and human umbilical vein endothelial cells (HUVECs). Bioinformatics analysis was employed to predict the binding relationship of CKAP2 and TFDP1, which was confirmed through dual luciferase reporter assay and immunoprecipitation assay. Furthermore, we injected human colorectal carcinoma HCT116 cells into mice flanks, and we injected Luciferase-labeled HCT116 cells into mice tail vein. HE staining was used to detect tumor nodules. As a result, high CKAP2 expression was found in CRC cells and tissues. CKAP2 silencing reduced CRC cell migration, invasion, proliferation, and epithelial-mesenchymal transition. Moreover, CKAP2 expression was positively associated with M2 macrophage levels. CKAP2 promoted protein expression of CD86, CD206, IL-1β, and CCL17. Moreover, CKAP2 promoted the proliferation of HUVECs and angiogenesis via affecting the tumor microenvironment (TME). We also found that CKAP2 could interact with TFDP1. The inhibitory impacts of TFDP1 downregulation on CRC cell' proliferation, migration, and invasion were reversed via CKAP2 overexpression. In vivo silencing of CKAP2 repressed tumor growth and metastasis. Overall, CKAP2 was positively regulated by TFDP1, which promoted tumorigenesis and metastasis in CRC.
BibTeX
@article{zhong2024ckap,
  author = {Zhiqiang Zhong and Shi Cheng and Yang Liu},
  title = {{CKAP2 Regulated by TFDP1 Promotes Metastasis and Proliferation of Colorectal Cancer through Affecting the Tumor Microenvironment}},
  journal = {Journal of Microbiology and Biotechnology},
  year = {2024},
  doi = {10.4014/jmb.2407.07008},
}
Figure